Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

© 2018 American Medical Association. All rights reserved. IMPORTANCE Studies of neoadjuvant chemotherapy regimens using anthracyclines followed by taxanes have reported a doubling of pathological complete remission (pCR) rates compared with anthracycline-based regimens alone. A reverse sequence did...

Full description

Bibliographic Details
Main Authors: Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., Chacon, J., Chan, Arlene, Morales, S., Alvarez, I., Plazaola, A., Zambetti, M., Redfern, A., Dittrich, C., Dent, R., Magazzu, D., De Fato, R., Valagussa, P., Tusquets, I.
Format: Journal Article
Published: 2018
Online Access:http://hdl.handle.net/20.500.11937/69018

Internet

http://hdl.handle.net/20.500.11937/69018

Similar Items